(Q46261836)

20 December 2017

title

Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug (English)

1 reference

20 December 2017

0 references

0 references

K S Fenner

1

1 reference

20 December 2017

M D Troutman

2

1 reference

20 December 2017

S Kempshall

3

1 reference

20 December 2017

J A Cook

4

1 reference

20 December 2017

J A Ware

5

1 reference

20 December 2017

D A Smith

6

1 reference

20 December 2017

C A Lee

7

1 reference

20 December 2017

language of work or name

English

0 references

publication date

5 November 2008

1 reference

20 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

20 December 2017

volume

85

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

page(s)

173-181

1 reference

20 December 2017

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

A general pattern for substrate recognition by P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

The complexities of hepatic drug transport: current knowledge and emerging concepts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Transporter-mediated drug interactions: clinical implications and in vitro assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Mechanisms, manifestations, and management of digoxin toxicity in the modern era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

A concurrent audit of high digoxin plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Clearance concepts in pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Rapid assessment of P-glycoprotein inhibition and induction in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

The digoxin-amiodarone interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Clinical pharmacokinetics of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Carvedilol increases the systemic bioavailability of oral digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Digoxin and cimetidine: investigation of the potential for a drug interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

The interaction of the calcium antagonist RO 40‐5967 with digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Dose-dependence of the nifedipine-digoxin interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Itraconazole decreases renal clearance of digoxin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Effect of quinidine on digoxin bioavailability

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Drug interactions with digoxin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

A regulatory viewpoint on transporter-based drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

The effects of captopril on serum digoxin levels in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

The diltiazem-digoxin interaction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Comparative effects of verapamil and isradipine on steady-state digoxin kinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Effect of two different doses of nitrendipine on steady-state plasma digoxin level and systolic time intervals

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Interaction between digoxin and calcium antagonists and antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Effect of troglitazone on steady-state pharmacokinetics of digoxin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.195

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.195

1 reference

20 December 2017

1 reference

20 December 2017